Zealand Pharma A/S

Zealand Pharma A/S is a Danish biotechnology company dedicated to the discovery, design, and development of peptide-based medicines, primarily focusing on obesity and metabolic health. Headquartered in Copenhagen, Denmark, with operations in Boston, Massachusetts, and New York City, USA, the company aims to become a generational biotech leader in its field.

Zealand Pharma's therapeutic focus areas include obesity, rare diseases such as congenital hyperinsulinism and short bowel syndrome, and chronic inflammation. The company boasts a robust pipeline of novel candidates, with over ten drug candidates having advanced into clinical development, and two products already on the market. Key pipeline assets include petrelintide, survodutide, dasiglucagon, glepaglutide, and ZP9830. Zealand Pharma frequently engages in strategic partnerships for co-development and commercialization to extend its capabilities.

Under the leadership of CEO Dr. Adam Steensberg, Zealand Pharma unveiled its "Metabolic Frontier 2030" strategy in December 2025, targeting five product launches and more than ten clinical pipeline programs by 2030, leveraging its peptide expertise and AI-driven drug discovery. Recent notable advancements include progressing petrelintide to Phase 3 trials in collaboration with Roche and positive Phase 3 results for survodutide, developed with Boehringer Ingelheim, demonstrating significant weight loss in obesity trials. The company reported substantial revenue growth in Q3 2025, largely driven by upfront payments from its strategic partnerships.

Latest updates

Zealand Pharma Taps Novo Nordisk Veteran for Board Amid Commercial Push

Event summary

  • Zealand Pharma proposes the election of Camilla Sylvest to its Board of Directors at an Extraordinary General Meeting on May 26, 2026.
  • Sylvest previously held the role of Executive Vice President for Global Commercial Strategy at Novo Nordisk, a major competitor in metabolic health.
  • She currently serves on the boards of argenx SE and Getinge AB.
  • Sylvest’s appointment is subject to shareholder approval.

The big picture

Zealand Pharma's move to add Camilla Sylvest to its board underscores the increasing importance of commercial expertise in the biotech sector, particularly for companies focused on complex therapeutic areas like obesity and metabolic health. The appointment signals a strategic shift towards greater self-sufficiency in commercialization, reducing reliance on partnerships and potentially increasing profitability. Sylvest’s background at Novo Nordisk, a company with significant market share, suggests Zealand Pharma is seeking to accelerate its own commercial capabilities.

What we're watching

Commercial Execution
Sylvest’s experience will be tested as Zealand Pharma attempts to establish a commercial footprint, and the board's ability to support this transition will be key to success.
Shareholder Alignment
The outcome of the shareholder vote will reveal the degree to which investors prioritize commercial expertise on the board, potentially signaling broader expectations for the company’s strategy.
Novo Nordisk Overlap
The potential for Sylvest to bring competitive insights from her time at Novo Nordisk warrants monitoring, as it could influence Zealand Pharma’s positioning within the crowded metabolic health market.

Roche, Zealand Pharma Advance Amylin Analog Petrelintide to Phase 3 Trials

Event summary

  • Zealand Pharma and Roche are advancing petrelintide, an amylin analog, into Phase 3 trials for chronic weight management, planned to begin in 2H 2026.
  • Phase 2 (ZUPREME-1) data showed double-digit weight loss with placebo-like tolerability.
  • The Phase 3 program will evaluate efficacy, safety, and tolerability in adults with obesity or overweight and weight-related comorbidities.
  • Zealand Pharma and Roche entered an exclusive collaboration and licensing agreement in 2025.
  • A Phase 2 trial combining petrelintide and Roche’s enicepatide (CT-388) is planned for 2Q 2026.

The big picture

The advancement of petrelintide represents a significant step in the ongoing race to develop more effective and tolerable weight management therapies. The obesity market is a multi-billion dollar opportunity, and the collaboration between Zealand Pharma and Roche, a major pharmaceutical player, underscores the growing recognition of amylin analogs as a potential therapeutic avenue. The combination strategy with Roche’s enicepatide suggests a focus on maximizing efficacy and addressing the limitations of monotherapy.

What we're watching

Clinical Efficacy
The Phase 3 trial results will be critical in determining whether petrelintide’s efficacy can be replicated in a larger, more diverse patient population, and whether it offers a clinically meaningful advantage over existing therapies.
Combination Strategy
The success of the planned Phase 2 trial combining petrelintide and enicepatide will significantly influence Roche’s commercial strategy and the overall value proposition of petrelintide.
Market Dynamics
The competitive landscape in the weight management market is rapidly evolving, and petrelintide’s success will depend on its ability to differentiate itself from emerging GLP-1/GIP dual agonists and other novel therapies.

Zealand Pharma Royalty Stream Boosted as Boehringer's Survodutide Shows Strong Weight Loss

Event summary

  • Boehringer Ingelheim’s survodutide, a glucagon/GLP-1 dual agonist licensed from Zealand Pharma, achieved a 16.6% average weight loss in Phase 3 SYNCHRONIZE-1 trial participants after 76 weeks.
  • The trial met both primary endpoints for weight loss and a key secondary endpoint for waist circumference reduction, indicating broader metabolic health improvements.
  • Zealand Pharma is eligible for high single to low double-digit royalties on global survodutide sales and up to EUR 315 million in milestone payments.
  • Survodutide is also being evaluated in trials targeting metabolic dysfunction-associated steatohepatitis (MASH).

The big picture

The success of survodutide validates the dual-agonist approach to obesity treatment, a rapidly evolving area with significant commercial potential given the global prevalence of overweight and obesity. Zealand Pharma’s royalty structure provides a contingent revenue stream tied to Boehringer’s commercial execution, but also exposes them to the risks inherent in a partnered drug development model. The focus on MASH treatment adds another layer of potential revenue, but also introduces additional regulatory hurdles and clinical trial complexity.

What we're watching

Clinical Data
Full data from the SYNCHRONIZE-1 and SYNCHRONIZE-MASLD trials, to be presented at the ADA 2026 Scientific Sessions, will be crucial in assessing the robustness of the initial topline results and potential regulatory pathways.
Commercialization
Boehringer Ingelheim’s broader metabolic health R&D program, including oral treatments, will determine the long-term competitive landscape and potential cannibalization of survodutide’s market share.
Regulatory Risk
The FDA and other regulatory bodies’ assessment of survodutide’s safety profile, particularly regarding gastrointestinal events, will significantly impact its approval timeline and market access.
CID: 1908